查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1924717

核医放射性药物市场按类型、技术、放射性示踪剂、最终用户和应用划分－全球预测（2026-2032 年）

Nuclear Radiopharmaceutical Market by Type, Technology, Radiotracer, End User, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，核医放射性药物市场价值将达到 64.4 亿美元，到 2026 年将成长至 69 亿美元，到 2032 年将达到 113 亿美元，复合年增长率为 8.37%。

关键市场统计数据
基准年 2025 64.4亿美元
预计年份：2026年 69亿美元
预测年份 2032 113亿美元
复合年增长率 (%) 8.37%

一份策略性入门指南，概述了影响核放射性药物在整个医疗保健系统中应用的临床作用、生产基础设施和监管趋势。

核放射性药物融合了先进化学、精准医学和诊断影像技术，使临床医生能够可视化生理过程并以分子特异性治疗疾病。本导论阐述了该领域的临床和技术背景，阐明了放射性示踪剂、放射性核种疗法和辅助性递送系统如何整合到现代治疗方案中。此外，本导论还概述了不断发展的生产方法和法规结构如何影响其在医院、影像中心和研究实验室的应用。

治疗诊断学、分散式同位素生产、自动化和监管现代化等融合趋势将如何重塑价值炼和临床应用？

核子医学领域正经历一场变革浪潮，这场变革正在重塑临床实务、供应链和经营模式。诊疗治疗诊断学） ——一种将诊断与标靶放射性核治疗相结合的综合方法——在促进核医学医师、肿瘤医师和放射性药物药剂师之间的跨学科合作方面发挥着核心作用。这种转变强调伴随诊断，将患者与治疗方法相匹配，从而加速了精准医疗的进程，并提升了放射性药物研发的临床提案。

评估关税政策变化对核医放射性药物生态系中供应链、生产决策和采购行为的连锁反应。

调整关税制度的政策变化会透过增加投入成本、改变竞争格局和加强策略在地化，对放射性药物生态系统产生连锁反应。如果设备、原料或前驱物同位素的进口关税提高，製造商必须评估是否自行承担成本、将其转嫁给医疗服务提供者，或是重组供应链。每一种选择都会产生临床和商业性影响，因为稳定的价格和可靠的供应对于接受常规诊断和时间敏感型治疗的患者至关重要。

整合细分洞察，将治疗方式、放射性示踪剂特性、最终用户需求和临床应用优先顺序连结起来，从而指南策略选择。

细分市场层面的趋势分析揭示了不同的需求驱动因素、临床路径和营运要求，从而指南产品开发和市场推广策略。依应用领域（诊断/治疗）分析放射性物质的使用情况，显示出供应炼和监管要求的显着差异：诊断流程包括PET和SPECT模式，其中PET的生产主要围绕F-18示踪剂，而SPECT通常使用Technetium-99m。治疗应用主要以碘-131用于甲状腺疾病和镏-177用于胜肽受体放射性核素治疗主导，每种应用在剂量、安全性和分销方面都有其独特的考量。

美洲、欧洲、中东和非洲以及亚太地区的区域基础设施、监管差异和临床应用模式将如何决定战略进入和扩张选择。

区域趋势影响着生产能力、监管方式、临床应用模式和伙伴关係机会，因此需要製定具有地理针对性的策略。在美洲，完善的临床基础设施和强大的专业设施网络支持着先进PET示踪剂和放射性核素疗法的快速应用。报销系统和集中式临床试验网络促进了新型治疗诊断学的应用，同时也对临床效用和成本效益的验证提出了更高的要求。

主要企业的定位和合作趋势揭示了製造规模、日益复杂的监管以及整合服务模式如何驱动竞争优势。

公司层面的发展趋势反映了专业化、垂直整合和协作模式的结合，这些模式共同塑造了当前的竞争格局。大型医疗设备製造商和放射性药物开发商正在投资于整合同位素生产、自动化合成模组和伴随诊断的解决方案，以缩短临床应用时间并提高不同试验点之间的一致性。同时，专业的合约研发生产机构 (CDMO) 和发生器製造商在帮助小规模创新企业无需大量前期投资即可扩大生产规模方面发挥着至关重要的作用。

产业领导者可以立即采取哪些具体策略和营运步骤，以增强韧性、加速应用并获取放射性药物领域的临床价值

为了充分利用不断变化的放射性药物市场环境，企业领导者应采取一系列切实可行的措施，兼顾短期韧性和长期成长。优先考虑供应来源多元化，并在经济条件允许的情况下投资本地生产能力，可以降低贸易中断和关税带来的风险。与合约研发生产机构 (CDMO) 和区域製造商建立策略联盟，既能加快市场准入，又能降低资本密集度。实施模组化、自动化的合成和包装平台，可以提高多个生产基地的生产效率一致性，并降低营运风险。

本报告采用透明的混合方法，结合专家访谈、技术文献综合和多方资讯来源检验，以确保研究结果具有可操作性和检验。

本报告的研究结合了质性专家对话、系统性文献检验和三角验证法，以确保证据基础的稳健性和平衡性。关键投入包括与临床医生、生产专家和供应链经理进行结构化访谈，以了解实际营运中的限制因素、临床应用驱动因素和采购考量。此外，还与放射化学和法规事务专家进行了技术咨询，以检验关于生产方法、稳定性挑战和合规性要求的假设。

对汇聚的科学、营运和政策力量进行简明扼要、综合分析，这些力量将决定哪些组织能够在推动核放射性药物医学方面取得成功。

核医放射性药物正处于关键的转折点，科学创新、生产现代化和政策演变在此交汇融合，创造了巨大的临床和商业性机会。治疗诊断学的兴起、生产技术的多元化以及对自动化和监管清晰度的日益重视，共同扩大了诊断示踪剂和标靶治疗的实际应用范围。整合生产製造、临床证据产生和策略伙伴关係的相关人员，将更有能力把技术可能性转化为对病人的实际影响。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 核医放射性药物市场（按类型划分）

  • 诊断
  • 治疗

9. 按技术分類的核医放射性药物市场

  • PET
  • SPECT

第十章 核医放射性药物市场（依放射性示踪剂划分）

  • F-18
  • 碘-131
  • 镏-177
  • Tc-99M

第十一章 核医放射性药物市场（依最终用户划分）

  • 医院
  • 诊断影像中心
  • 研究所

第十二章 核医放射性药物市场（依应用领域划分）

  • 循环系统
  • 神经病学
  • 肿瘤学

第十三章 核医放射性药物市场（依地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 核医放射性药物市场（依类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国核医放射性药物市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

16. 美国核医放射性药物市场

第十七章 中国核医放射性药物市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Advanced Accelerator Applications SA
  • Bayer AG
  • Bracco Imaging SpA
  • BWXT Medical Ltd.
  • Cardinal Health, Inc.
  • Clarity Pharmaceuticals Ltd.
  • Curium Pharma SAS
  • Eckert & Ziegler SE
  • Eli Lilly and Company
  • GE HealthCare Technologies Inc.
  • ITM Isotope Technologies Munich SE
  • Jubilant Pharmova Limited
  • Lantheus Holdings, Inc.
  • NorthStar Medical Radioisotopes, LLC
  • Novartis AG
  • RayzeBio, Inc.
  • Shanghai United Imaging Healthcare Co., Ltd.
  • Siemens Healthineers AG
  • SOFIE Biosciences, Inc.
  • Telix Pharmaceuticals Limited
Product Code: MRR-7A380DA7C44A

The Nuclear Radiopharmaceutical Market was valued at USD 6.44 billion in 2025 and is projected to grow to USD 6.90 billion in 2026, with a CAGR of 8.37%, reaching USD 11.30 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.44 billion
Estimated Year [2026] USD 6.90 billion
Forecast Year [2032] USD 11.30 billion
CAGR (%) 8.37%

A strategic primer that frames the clinical roles, production enablers, and regulatory vectors shaping nuclear radiopharmaceutical adoption across healthcare systems

Nuclear radiopharmaceuticals occupy a distinct intersection of advanced chemistry, precision medicine, and diagnostic imaging, enabling clinicians to visualize physiological processes and treat disease with molecular specificity. This introduction establishes the clinical and technological context for the dossier, clarifying how radiotracers, radionuclide therapies, and supporting delivery systems integrate into contemporary care pathways. It also outlines how evolving production modalities and regulatory frameworks influence adoption across hospitals, imaging centers, and research institutes.

Radiopharmaceuticals serve two primary clinical roles: diagnostic imaging, which includes positron emission tomography and single-photon emission computed tomography applications, and therapeutic interventions that deliver targeted radioisotopes to diseased tissues. Diagnostic radiotracers such as F-18 derivatives provide high-resolution metabolic and molecular information, while technetium-99m-based agents remain essential for a broad range of routine imaging. On the therapeutic side, iodine-131 continues to underpin thyroid treatments, and lutetium-177-labeled agents are establishing new paradigms in peptide receptor radionuclide therapy.

Advances in production-spanning cyclotron-based synthesis of short-lived PET isotopes, generator systems for rapid technetium-99m access, and improved radiolabeling automation-are key enablers of broader clinical deployment. Meanwhile, regulatory emphasis on GMP-compliant manufacturing, dose standardization, and patient safety drives capital investments and process innovation. Together, these technical and regulatory vectors set the stage for strategic decisions by manufacturers, clinical operators, and investors seeking to participate in a field that is rapidly moving from niche specialty use toward more integrated roles in oncology, cardiology, and neurology.

How converging trends in theranostics, decentralized isotope production, automation, and regulatory modernization are redefining value chains and clinical adoption

The nuclear radiopharmaceutical arena is undergoing transformative shifts that are remaking clinical practice, supply chains, and commercial models. Theranostics-an integrated approach combining diagnostics and targeted radionuclide therapy-has emerged as a rallying point, fostering cross-disciplinary collaboration between nuclear medicine physicians, oncologists, and radiopharmacists. This shift emphasizes companion diagnostics that match patients to therapies, accelerating precision medicine pathways and elevating the clinical value proposition of radiopharmaceutical development.

Concurrently, decentralization of isotope production is gaining momentum. Investments in regional cyclotron installations and compact accelerator platforms are reducing reliance on distant centralized suppliers and high-risk distribution routes. This trend enhances local resilience and shortens time-to-patient for short-lived PET isotopes, while generator-based solutions continue to offer reliable access to technetium-99m in settings without advanced infrastructure. Such production plurality drives competitiveness and encourages novel business models that pair manufacturing services with clinical support.

On the technology front, automation of radiochemistry workflows and the standardization of kits and cassettes reduce variability and lower barriers to clinical adoption. Image quantification improvements, coupled with artificial intelligence-enabled interpretation, are improving diagnostic precision and enabling more objective endpoints in clinical trials. Regulatory pathways are also evolving to accommodate the unique characteristics of radiopharmaceuticals, with authorities increasingly recognizing the need for tailored guidance on manufacturing controls, stability testing, and clinical endpoints. These combined dynamics are reshaping value chains, creating new entrants, and prompting legacy players to rethink partnerships, distribution strategies, and investment priorities.

Assessing how changes in tariff policy can ripple across supply chains, production decisions, and procurement behavior in the nuclear radiopharmaceutical ecosystem

Policy shifts that adjust tariff regimes can cascade through the radiopharmaceutical ecosystem by increasing input costs, altering competitive dynamics, and incentivizing strategic localization. When import duties rise on equipment, raw materials, or precursor isotopes, manufacturers must evaluate whether to absorb costs, pass them to healthcare providers, or reconfigure supply chains. Each choice carries clinical and commercial implications, because stable pricing and reliable supply are essential for routine diagnostic schedules and for patients receiving time-sensitive therapeutic doses.

Higher tariffs can catalyze nearshoring decisions, prompting investments in domestic cyclotron capacity, generator assembly facilities, and local radiopharmacy services. Such investments mitigate exposure to cross-border trade friction but require significant capital, skilled personnel, and regulatory approvals. In the interim, increased tariffs can compress margins for external suppliers and distributors, incentivizing consolidation or vertical integration among manufacturers and healthcare systems seeking to secure availability and control costs.

Tariff-driven cost pressures also affect instrument manufacturers and suppliers of consumables, potentially slowing procurement of imaging devices or automated synthesis modules in cost-sensitive settings. As a result, imaging centers and hospitals may prioritize technologies with the most favorable total cost of ownership or favor suppliers with local support networks. Over time, differential tariff impacts can shift competitive advantages between domestic and foreign producers, influencing partner selection, contract negotiations, and long-term procurement strategies.

Importantly, the interaction between tariffs and regulatory policies magnifies the effect of trade measures. Regulatory incentives for domestic production, such as streamlined facility approvals or procurement preferences, can reinforce the localization trend. Conversely, exemptions for critical medical supplies or diplomatic arrangements may alleviate immediate pressures. Stakeholders should therefore monitor both trade policy developments and corresponding regulatory responses, assess supply chain vulnerabilities, and model scenarios that prioritize treatment continuity and patient safety while preserving commercial viability.

Integrated segmentation insights that connect modality, radiotracer specifics, end-user requirements, and clinical application priorities to inform strategic choices

Segment-level dynamics reveal differentiated demand drivers, clinical pathways, and operational requirements that should inform product development and go-to-market strategies. Based on type, activity splits between diagnostic and therapeutic uses show distinct supply chain and regulatory needs: diagnostic workflows encompass PET and SPECT modalities where PET production frequently revolves around F-18 tracers and SPECT commonly leverages technetium-99m; therapeutic applications are led by iodine-131 for thyroid conditions and lutetium-177 for peptide receptor radionuclide therapy, each with unique dosing, safety, and distribution considerations.

Viewed through the lens of technology, PET and SPECT platforms remain foundational, with PET centering on F-18 production pathways that demand cyclotron access and rapid distribution, while SPECT utilizes Tc-99m that benefits from generator availability and kit-based radiochemistry. End users span hospitals, imaging centers, and research institutes, and each setting imposes different procurement cycles, staffing expertise, and regulatory compliance burdens that affect the selection of tracers, automation levels, and service agreements.

Radiotracer segmentation highlights the centrality of F-18, I-131, Lu-177, and Tc-99m. F-18 applications are often exemplified by FDG kits and protocols optimized for metabolic imaging; I-131 remains indispensable for thyroid therapeutics with well-established dosing regimens; Lu-177 is increasingly associated with peptide receptor radionuclide therapy programs that require coordinated patient selection pathways and specialized handling; and Tc-99m maintains broad utility where generators and kits enable flexible, on-site radiopharmacy operations.

Application-based segmentation across cardiovascular, neurology, and oncology underscores clinical prioritization. Oncology leads adoption of theranostic pairings and targeted therapies, neurology benefits from tracers that characterize neurodegenerative disease biology, and cardiovascular imaging relies on robust protocols for perfusion and viability assessment. Integrating these segmentation perspectives helps stakeholders align manufacturing scale, distribution models, and clinical support services with distinct operational realities across diagnostic and therapeutic domains.

How regional infrastructure, regulatory diversity, and clinical adoption patterns across the Americas, Europe Middle East & Africa, and Asia-Pacific determine strategic entry and scaling choices

Regional dynamics shape production capacity, regulatory approaches, clinical adoption patterns, and partnership opportunities in ways that demand geographically informed strategies. In the Americas, established clinical infrastructures and a strong network of specialized centers support rapid uptake of advanced PET tracers and radionuclide therapies; reimbursement mechanisms and centralized trial networks often facilitate the introduction of new theranostics but can also create high expectations for demonstration of clinical utility and cost-effectiveness.

In Europe, the Middle East & Africa, regulatory heterogeneity, disparate infrastructure maturity, and diverse healthcare financing models produce a patchwork of demand signals. Western European centers with robust nuclear medicine programs drive early adoption of complex radiotherapeutics, while segments within the broader region face constraints that favor generator-based solutions and kits. Strategic partnerships, regional manufacturing hubs, and technology transfer programs can accelerate access where infrastructure gaps exist, but stakeholders must navigate varied approval pathways and procurement norms.

Asia-Pacific presents a rapidly evolving landscape where investments in cyclotron facilities, growing clinical trial activity, and expanding healthcare coverage underpin rising interest in both diagnostics and therapeutics. National priorities to build domestic capacity and secure supply chains are fostering localized production initiatives, while the scale and diversity of healthcare systems across the region create opportunities for tiered product offerings and flexible business models. Across all regions, aligning commercialization plans with local regulatory expectations, clinician training priorities, and logistical realities remains essential for successful market entry and sustained adoption.

Key corporate positioning and partnership trends revealing how manufacturing scale, regulatory sophistication, and integrated service models drive competitive advantage

Company-level dynamics reflect a mix of specialization, vertical integration, and collaborative models that collectively define the competitive terrain. Leading device manufacturers and radiopharmaceutical developers are investing in integrated solutions that combine isotope production, automated synthesis modules, and companion diagnostics to shorten clinical implementation timelines and improve consistency across sites. At the same time, specialized contract development and manufacturing organizations (CDMOs) and generator producers play a pivotal role in enabling smaller innovators to scale without large upfront capital investments.

Partnerships between clinical research organizations, academic centers, and industry are a common route to de-risk early-stage development and validate therapeutic hypotheses. Licensing agreements and co-development partnerships allow companies to combine proprietary ligands, radiochemistry know-how, and clinical expertise to accelerate registration pathways. Meanwhile, strategic acquisitions are used to secure manufacturing capacity, expand geographic reach, and internalize critical supply chain capabilities.

Companies that prioritize regulatory intelligence, invest in robust GMP-compliant manufacturing, and maintain responsive technical support networks enjoy stronger adoption in clinical settings that require high reliability. Differentiation increasingly arises from the ability to offer end-to-end solutions-spanning tracer availability, quality control, clinical training, and reimbursement support-rather than from single product features alone. For investors and corporate strategists, evaluating potential partners requires careful assessment of manufacturing redundancy, intellectual property position, and demonstrated clinical outcomes to ensure alignment with long-term therapeutic and diagnostic roadmaps.

Concrete strategic and operational moves that industry leaders can implement immediately to build resilience, accelerate adoption, and capture clinical value in radiopharmaceuticals

Leaders aiming to capitalize on the evolving radiopharmaceutical environment should pursue a set of pragmatic actions that balance near-term resilience with long-term growth. Prioritizing diversification of supply sources and investing in localized production capacity where economically justified can reduce exposure to trade disruptions and tariffs, while strategic alliances with CDMOs or regional manufacturers can accelerate market entry with lower capital intensity. Implementing modular, automated synthesis and packaging platforms will improve throughput consistency and reduce operational risk across multiple sites.

Clinically, organizations should invest in evidence generation that demonstrates comparative effectiveness and patient-centered outcomes for new radiotracers and therapies, enabling stronger reimbursement positioning. Building multidisciplinary clinician engagement programs that include nuclear medicine, oncology, cardiology, and neurology stakeholders will support appropriate patient selection and protocol standardization. From a commercial standpoint, packaging service bundles that combine tracer supply, technical training, and regulatory support can differentiate offerings and foster long-term customer relationships.

Operationally, strengthening cold chain logistics, ensuring redundant supply pathways, and maintaining robust quality management systems will protect continuity of care. Decision-makers should also establish clear scenario planning processes to model the impact of trade policy changes, technological disruptions, or shifts in clinical guidelines, and use those scenarios to inform capital allocation and partnership choices. Taken together, these actions create a resilient platform from which organizations can scale clinical programs and capture the value emerging from theranostic innovations.

A transparent mixed-methods approach combining expert interviews, technical literature synthesis, and cross-source triangulation to ensure actionable and validated insights

The research behind this report combines qualitative expert engagement with systematic document review and triangulation to ensure a balanced and defensible evidence base. Primary inputs include structured interviews with clinicians, manufacturing experts, and supply chain managers to capture real-world operational constraints, clinical adoption drivers, and procurement considerations. These conversations are complemented by technical consultations with radiochemistry specialists and regulatory affairs professionals to validate assumptions about production methods, stability challenges, and compliance requirements.

Secondary research involved reviewing peer-reviewed literature, regulatory guidance documents, clinical trial registries, and publicly available company disclosures to map technology capabilities, clinical trial outcomes, and product approvals. Where available, white papers and technical notes on cyclotron operations, generator technology, and automated synthesis modules were used to clarify production characteristics and quality control practices. Information from logistics and healthcare infrastructure studies helped contextualize regional differences in deployment feasibility.

Data synthesis employed a triangulation approach that reconciled insights from interviews, technical documents, and clinical literature to identify consistent patterns and surface divergent viewpoints. Sensitivity analyses on operational scenarios were used to stress-test strategic implications, and iterative validation sessions with subject matter experts refined the final narrative. Throughout, methodological rigor emphasized transparency in source provenance, clarity about assumptions, and attention to clinical relevance to ensure the findings support practical decision-making.

A concise synthesis of the convergent scientific, operational, and policy forces that will determine which organizations succeed in advancing nuclear radiopharmaceutical care

Nuclear radiopharmaceuticals stand at a pivotal juncture where scientific innovation, production modernization, and evolving policy intersect to create significant clinical and commercial opportunities. The ascendancy of theranostics, the diversification of production technologies, and the increasing emphasis on automation and regulatory clarity are collectively expanding the practical reach of both diagnostic tracers and targeted therapies. Stakeholders that align manufacturing, clinical evidence generation, and strategic partnerships will be best positioned to translate technical promise into patient impact.

At the same time, trade policy shifts and regional infrastructure disparities introduce complexity that requires proactive planning. By prioritizing supply chain resilience, targeted investments in localized capabilities where appropriate, and robust clinical engagement to demonstrate value, organizations can navigate uncertainty while accelerating adoption. Ultimately, success will depend on the ability to integrate technical excellence with pragmatic operational strategies that ensure consistent access to high-quality radiopharmaceuticals for patients across diverse healthcare settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Nuclear Radiopharmaceutical Market, by Type

  • 8.1. Diagnostic
  • 8.2. Therapeutic

9. Nuclear Radiopharmaceutical Market, by Technology

  • 9.1. Pet
  • 9.2. Spect

10. Nuclear Radiopharmaceutical Market, by Radiotracer

  • 10.1. F-18
  • 10.2. I-131
  • 10.3. Lu-177
  • 10.4. Tc-99M

11. Nuclear Radiopharmaceutical Market, by End User

  • 11.1. Hospitals
  • 11.2. Imaging Centers
  • 11.3. Research Institutes

12. Nuclear Radiopharmaceutical Market, by Application

  • 12.1. Cardiovascular
  • 12.2. Neurology
  • 12.3. Oncology

13. Nuclear Radiopharmaceutical Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Nuclear Radiopharmaceutical Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Nuclear Radiopharmaceutical Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Nuclear Radiopharmaceutical Market

17. China Nuclear Radiopharmaceutical Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Advanced Accelerator Applications S.A.
  • 18.6. Bayer AG
  • 18.7. Bracco Imaging S.p.A.
  • 18.8. BWXT Medical Ltd.
  • 18.9. Cardinal Health, Inc.
  • 18.10. Clarity Pharmaceuticals Ltd.
  • 18.11. Curium Pharma SAS
  • 18.12. Eckert & Ziegler SE
  • 18.13. Eli Lilly and Company
  • 18.14. GE HealthCare Technologies Inc.
  • 18.15. ITM Isotope Technologies Munich SE
  • 18.16. Jubilant Pharmova Limited
  • 18.17. Lantheus Holdings, Inc.
  • 18.18. NorthStar Medical Radioisotopes, LLC
  • 18.19. Novartis AG
  • 18.20. RayzeBio, Inc.
  • 18.21. Shanghai United Imaging Healthcare Co., Ltd.
  • 18.22. Siemens Healthineers AG
  • 18.23. SOFIE Biosciences, Inc.
  • 18.24. Telix Pharmaceuticals Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY RADIOTRACER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY DIAGNOSTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY DIAGNOSTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY PET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY PET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY PET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY SPECT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY SPECT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY SPECT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY RADIOTRACER, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY F-18, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY F-18, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY F-18, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY I-131, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY I-131, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY I-131, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY LU-177, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY LU-177, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY LU-177, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TC-99M, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TC-99M, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TC-99M, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY IMAGING CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY IMAGING CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY IMAGING CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY RADIOTRACER, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY RADIOTRACER, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY RADIOTRACER, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY RADIOTRACER, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY RADIOTRACER, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY RADIOTRACER, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 89. AFRICA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY RADIOTRACER, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY RADIOTRACER, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY RADIOTRACER, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. ASEAN NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 105. GCC NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GCC NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. GCC NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 108. GCC NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY RADIOTRACER, 2018-2032 (USD MILLION)
  • TABLE 109. GCC NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. GCC NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPEAN UNION NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPEAN UNION NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPEAN UNION NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY RADIOTRACER, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPEAN UNION NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPEAN UNION NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. BRICS NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 120. BRICS NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY RADIOTRACER, 2018-2032 (USD MILLION)
  • TABLE 121. BRICS NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. BRICS NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. G7 NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. G7 NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. G7 NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 126. G7 NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY RADIOTRACER, 2018-2032 (USD MILLION)
  • TABLE 127. G7 NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. G7 NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 129. NATO NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. NATO NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. NATO NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 132. NATO NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY RADIOTRACER, 2018-2032 (USD MILLION)
  • TABLE 133. NATO NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. NATO NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. UNITED STATES NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. UNITED STATES NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. UNITED STATES NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. UNITED STATES NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY RADIOTRACER, 2018-2032 (USD MILLION)
  • TABLE 140. UNITED STATES NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. UNITED STATES NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. CHINA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. CHINA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. CHINA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 145. CHINA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY RADIOTRACER, 2018-2032 (USD MILLION)
  • TABLE 146. CHINA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. CHINA NUCLEAR RADIOPHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)